News

PipelineReview.com43m
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes ...
PipelineReview.com49m
Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets
WALTHAM, MA, USA I July 9, 2025 I Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for ...
PipelineReview.com52m
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
BASEL, Switzerland / MUNICH, Germany I July 10, 2025 I NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...
PipelineReview.com52m
Zhimeng Biopharma’s Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
SHANGHAI, China I July 9, 2025 I Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative ...
PipelineReview.com2h
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
OSLO, Norway and CAMBRIDGE, MA, USA I July 9, 2025 I Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into ...
PipelineReview.com2h
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
CHICAGO, IL, USA I July 09, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted ...
PipelineReview.com2h
FDA approves updated label for Lilly’s Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer’s disease
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of ...
PipelineReview.com2h
Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine
PRAGUE, Czech Republic I July 9, 2025 I Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for ...
PipelineReview.com3h
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
MARTINSRIED, Germany, and MARSEILLE, France I July 10, 2025 I Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of ...
PipelineReview.com1d
Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen
NEW YORK, NY, USA I July 8, 2025 I Myrtelle Inc. (“Myrtelle” or the “Company”), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, ...
PipelineReview.com1d
Cerapedics Announces First U.S. Patient Treated with PearlMatrix™ P-15 Peptide Enhanced Bone Graft following FDA approval
AdventHealth Avista, an Orthopedic and Spine Center of Excellence, conducted the first lumbar fusion procedure with PearlMatrix Bone Graft, the first and only ...
PipelineReview.com1d
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
MIAMI, FL, USA and JERUSALEM, Israel I July 08, 2025 I OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced ...